A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Summary

The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a type of liver disease.

Timeline

Start

2023-03-31

Primary completion

2024-03-20

Completion

2024-03-20

Outcome

Outcome not reported

Stopped: “AstraZeneca have decided to not move forward with the development of the compound.”

Drugs

Indications